Safety and bioequivalency of three formulations of respiratory syncytial virus-enriched immunoglobulin.

AUTOR(ES)

Groothuis, J R

RESUMO

Respiratory syncytial virus (RSV) causes serious illness (lower respiratory illness) in preterm infants. RSV antibody-enriched immunoglobulin (RSVIG) that was lyophilized (LYO) protected against RSV lower respiratory illness. The Food and Drug Administration now requires an additional viral inactivation step (VI). We compared LYO, LYO-VI, and a more convenient liquid RSVIG (LIQ-VI) in 30 preterm infants (median age, 7 months; median weight, 5.4 kg). Infants were randomized to receive LYO (n = 10), LYO-VI (n = 10), or LIQ-VI (n = 10) in monthly infusions of 750 mg/kg of body weight per dose (December to March). Children were monitored closely for adverse reactions to RSVIG and for RSV illness.

Documentos Relacionados

• Synthesis of Double-Stranded RNA in a Virus-Enriched Fraction from Agaricus bisporus
• Severity of respiratory syncytial virus infections and immunoglobulin concentrations.
• Three-dimensional structure of an intact human immunoglobulin.
• Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections.
• Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children.